Using artificial intelligence to diagnose a range of diseases, Sophia Genetics, a Cambridge-based start-up and genetics testing company, has become the world's largest network for molecular diagnostics. Mike Lynch, whose firm Invoke Capital has invested $18m, said that other companies “will struggle to catch up.” Using and analysing data from 100 hospitals, the company will diagnose over 80,000 patients in 2016. The technology is being used by hospitals across America, including Johns Hopkins University Hospital in Baltimore, which uses it to screen blood samples taken at its emergency department.
Using artificial intelligence to diagnose a range of diseases, Sophia Genetics, a Cambridge-based start-up and genetics testing company, has become the world's largest network for molecular diagnostics. Mike Lynch, whose firm Invoke Capital has invested $18m, said that other companies “will struggle to catch up.” Using and analysing data from 100 hospitals, the company will diagnose over 80,000 patients in 2016. This data-rich ‘precision medicine,’ results in a faster and more accurate diagnosis, which in turn will lead to a specific, tailored treatment plan.